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Abstract
Mitoxantrone is a potent antitumor drug, widely used in the treatment of various cancers. In the
present study, we have investigated and compared the affinity of anticancer drug, mitoxantrone, to
EDTA-soluble chromatin (SE-chromatin), DNA and histones employing UV/Vis, fluorescence, CD
spectroscopy, gel electrophoresis and equilibrium dialysis techniques. The results showed that the
interaction of mitoxantrone with SE-chromatin proceeds into compaction/aggregation as revealed
by reduction in the absorbencies at 608 and 260 nm (hypochromicity) and disappearance of both
histones and DNA on the gels. Mitoxantrone interacts strongly with histone proteins in solution
making structural changes in the molecule as shown by CD and fluorescence analysis. The binding
isotherms demonstrate a positive cooperative binding pattern for the chromatin- mitoxantrone
interaction. It is suggested higher binding affinity of mitoxantrone to chromatin compared to DNA
implying that the histone proteins may play an important role in the chromatin- mitoxantrone
interaction process.
Mitoxantrone is a synthetic antineoplastic drug, structur-
ally similar to the anthracyclines, widely used as a potent
chemotherapeutic agent in the treatment of various can-
cers such as advanced breast cancer, lymphoma and leuke-
mia [1-3]. Widespread interest in mitoxantrone has arisen
because of its apparent lower risk of cardiotoxic effects
compared with the naturally occurring anthracyclines
[4,5].
Numerous studies on the mechanism of mitoxantrone
action indicate that nuclear DNA is the major target for
this drug [6,7]. The structure of mitoxantrone lacks the
amino sugar moiety and tetracyclic ring (A) of anthracy-
clines but has a planar anthraquinone ring which interca-
lates between DNA base pairs and the nitrogen-containing
side chains bind the negatively charged phosphate groups
of DNA [7,8]. Binding of mitoxantrone to DNA causes
DNA condensation and inhibits DNA replication and
RNA transcription [9-11]. Also it is a potent inhibitor of
topoisomeraseII, an enzyme known to be important for
the repair of damaged DNA and this leads to single and
double strand breaks [12].
The binding of mitoxantrone to DNA has been studied in
detail [13-15]. However, in the cell nucleus; DNA is com-
pacted into a complex structure built from the interaction
of histones with DNA named nucleosomes. These consist
of 145 base pairs DNA wrapped around an octamer of
core histones. There are 5 main histones: the linker his-
tones of the H1 family and 4 core histones (H2A, H2B, H3
and H4) which are arranged in an octamer form [16].
How the presence of chromosomal proteins affect and
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modulate the binding of intercalating drugs to DNA, is an
important question when trying to understand the mech-
anism of drug action at the chromatin level. To explore
this question, we employed several experiments designed
to clarify this question in more detail.
In the present study, we attempted to examine and com-
pare the effect of mitoxantrone on rat liver chromatin,
DNA and histone proteins in solution to further under-
stand the mechanism of drug action at the cellular chro-
matin level. The results provide evidence that
mitoxantrone shows different affinity to chromatin, DNA
and histones implying that the environment of chromatin
plays fundamental role in the drug-DNA interactions.
Materials and methods
Materials
Mitoxantrone hydrochloride (2 mg/ml in H2O) was pur-
chased from Helale Ahmar, Tehran, Iran (manufactured
by Ebewe Pharma Ges.m.b. Austria) stored at 4°C in the
dark. Before use, it was diluted to desired concentrations
with 10 mM Tris-HCl (pH 7.4) and its concentration was
determined spectrophotometrically using a molar extinc-
tion coefficient of 19 200 M-1 cm-1 at 608 nm. Microccocal
nuclease (MNase), proteinase K, ECoR1-Hind III digested
DNA marker, cocktail protease inhibitor were from Sigma
Chemical Company. Calf thymus DNA (Sigma) was dis-
solved in 10 mM Tris-HCl (pH 7.4), dialyzed overnight
against the same buffer and its concentration was deter-
mined using an extinction coefficient of 20 cm-1 mg-1 at
260 nm. Albino rats weighting of 150–200 gram of either
sex were used throughout the experiments.
Preparation of chromatin, DNA and histones
Nuclei were prepared from rat liver as described elsewhere
[17]. All steps were carried out at 4°C in the presence of
protease inhibitor PMSF at a final concentration of 1 mM
or cocktail protease inhibitor (1/100 V/V). EDTA soluble
chromatin was isolated according to the procedure
reported before [18] with some modifications. Briefly, the
purified nuclei were suspended in digestion buffer (0.25
M sucrose, 25 mM NaCl, 1 mM CaCl2 and 10 mM Tris-
HCl (pH 7.4)) and DNA content was determined by
measuring the absorbance at 260 nm. The nuclear suspen-
sion at A260 = 100 was digested with 3 units of microccoc-
cal nuclease/mg of DNA at 37°C for 10 min. The solution
was brought to 10 mM EDTA on ice, centrifuged at 8000
g for 5 min and then the chromatin solubilized in 0.25
mM EDTA (pH 8). The chromatin thus prepared desig-
nated as EDTA-soluble chromatin (SE-chromatin).
DNA was isolated from the SE-chromatin samples by pro-
teinase K digestion (1 μg of enzyme/10 μg of DNA) and
phenol-chloroform extraction method. The extracted
DNA was then resuspended in 10 mM Tris-HCl (pH 7.4).
The concentration of DNA in both, the SE-chromatin and
purified DNA, were determined spectrophotometrically
using an extinction coefficient of 20 cm-1 mg-1 at 260 nm.
Whole histone, consisting of all five histones, was
extracted from calf thymus by 0.3 N HCl as described by
Johns [19] and further purified using DEAE ion exchange
chromatography. The whole histone was dissolved in 10
mM Tris-HCl (pH 7.3) and after pH adjustment; the solu-
tion was stored at -20°C and used within a month.
UV/Vis Spectroscopy
The SE-chromatin, DNA and histones [100 μg/ml DNA or
histone in 10 mM Tris-HCl (pH 7.4)] were incubated indi-
vidually with appropriate concentrations of mitoxantrone
for 45 min at room temperature in the dark. Control sam-
ples containing equal volumes of SE chromatin, DNA and
histones in the same buffer were incubated along with the
drug treated samples under the same condition.
Mitoxantrone treated and the controls were subjected to
spectroscopic analysis using Shimadzo UV-160 spectro-
photometer, equipped with quartz cuvettes. The wave-
length of 400 nm was selected to detect the amount of
turbidity. After centrifugation at 8000 g for 1 min, absorb-
ance of the supernatants was recorded using multi λ sys-
tem.
Fluorescence Spectroscopy
The measurements were performed on a Carry Eclipse flu-
orescence spectrophotometer equipped with a thermo-
statically controlled cell holder at ambient temperature.
The monochromatic slits were set at 5 nm to reduce the
intensity of the signal depending on the experiment. All
samples were made in 10 mM Tris-HCl (pH 7.3) at 20°C
and quartz fluorescence cell of 1 cm path length was used.
Protein solution (5–10 μM) was titrated with aliquots of
mitoxantrone and equilibrated until a steady emission
reading was obtained. The accumulated volume of titra-
tion was less than 10 μl, so dilution effect was negligible.
The spectra were recorded between 290–410 nm after
excitation at 278 nm. Mitoxantrone, histones and amino
acid tyrosine were prepared individually in the same
buffer and their emission spectra recorded in the same
condition and used as a control.
Circular dichroism experiment
Circular dichroism (CD) experiment was performed using
CD spectrometer model 215 (AVIV instruments INC.).
The Far-UV CD spectra of histones in 10 mM Tris-HCl pH
7.3 and in the absence and presence of various concentra-
tions of mitoxantrone was recorded in the range of 190–
260 nm with a spectral resolution of 1 nm. The scan speed
was 20 nm/min and the response time was 0.3330 sec
with a band width of 1 nm. Quartz cell with a path lengthJournal of Biomedical Science 2009, 16:31 http://www.jbiomedsci.com/content/16/1/31
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of 10 mm was used and all measurements were carried out
at 25°C. Results are expressed as molar ellipticity
expressed as [ ], in deg × cm2 × dmol-1.
Gel electrophoresis
The supernatants obtained from the interaction of SE-
chromatin with various concentrations of mitoxantrone
were concentrated using Eppendorf concentrator (model
5301) and then analyzed on 15% SDS polyacrylamid gel
electrophoresis as described by Laemmli [20]. The gel was
stained with coomassie brilliant blue R 250, destained in
methanol/acetic acid and photographed.
Agarose (1.5%) gel electrophoresis was also carried out in
TBE buffer [89 mM Tris-borate, 2 mM EDTA (pH 8)] at a
constant voltage of 80 V for 1 h [21]. The gel was then
stained with ethidium bromide (5 μg/ml in distilled
water) and photographed.
Equilibrium dialysis
SE-chromatin and DNA were prepared in 10 mM Tris-HCl
(pH 7.4) and dialyzed against the same buffer containing
serial concentrations of mitoxantrone using Spectrum
Laboratories (USA) dialysis tubing at room temperature.
The equilibrium was achieved within 72 h at 23°C. The
total drug concentration (Ct) and the concentration of free
drug (Cf) in the dialysate were measured directly from the
absorbance at 608 nm before and after dialysis using
extinction coefficient of 19 200 M-1 cm-1. The amount of
bound drug (Cb) was obtained from Cb = Ct-Cf. Binding
parameters were determined from the plot of r/Cf versus r
according to Scatchard method [22], where r is the ratio of
bound drug to total base pair concentration and Cf is the
amount of free drug. In this presentation, n (the apparent
number of binding sites), is the intercept of the linear
region of the binding curve with the horizontal axis. Also
K (apparent binding constant) corresponds to the nega-
tive value of the slope of the curve. The Hill coefficient
value (nH) was determined from the slope of the ln (r/n-
r) versus ln Cf according to the Hill equation [23].
Results
Mitoxantrone shows higher affinity to chromatin 
compared to DNA
An experiment was designed using rat liver soluble chro-
matin fraction incubated in the presence and absence of
the various concentrations of mitoxantrone. Addition of
drug to SE-chromatin solution resulted in chromatin
aggregation and precipitation which could be detected by
monitoring the absorbance at 400 nm (turbidity). The
result is shown in Fig. 1. As is seen, gradual increase in
mitoxantrone concentration enhances turbidity of the
reaction mixture. Turbidity formation is slow at low con-
centrations of drug (up to 20 μM), but a sharp absorbance
changes is occurred upon increasing drug concentration
(between 20 and 40 μM).
To compare data with the DNA free in solution (in the
absence of chromatin proteins), DNA was isolated from
such SE-chromatin as described in the method section
(designated SE-DNA) and treated with various concentra-
tions of mitoxantrone in the same experimental condi-
tions mentioned for the SE-chromatin. Calf thymus DNA
was also used for comparison. The results obtained from
turbidity measurement are inserted in Fig. 1. The absorb-
ance changes of both SE-DNA and thymus DNA in the
presence of mitoxantrone exhibited similar but not iden-
tical binding pattern which differs considerably compared
to SE-chromatin- mitoxantrone complex pattern. In the
case of both DNAs used, the absorbance changes at 400
nm is very slow up to 80 μM of drug and then changes
slightly, thus much higher drug concentration is needed
to obtain saturation state.
In the next step, the precipitates were removed by brief
centrifugation and the clear supernatants were subjected
to UV/Vis spectroscopy measurements. The result of
absorbance changes at 260 nm is shown in Fig. 2. For the
SE-chromatin, and at low concentrations of drug (≤ 10
μM), a slight increase in the absorbance is observed, but at
higher drug values the absorbance is considerably
decreased and drops to zero at 40 μM of mitoxantrone.
Whereas in the case of thymus DNA and SE-DNA, the
Turbidity measurements at 400 nm of the interaction of vari- ous concentrations of mitoxantrone with SE-chromatin (dia- mond), SE-DNA (triangle) and thymus DNA (square) Figure 1
Turbidity measurements at 400 nm of the interac-
tion of various concentrations of mitoxantrone with 
SE-chromatin (diamond), SE-DNA (triangle) and thy-
mus DNA (square). The reaction was carried out in 10 
mM Tris-HCl (pH 7.5) and incubation time was 45 min at 
23°C. Results are average of 3 individual experiments.
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absorbance changes at 260 nm occurs beyond this range
(80 and 100 μM of mitoxantrone respectively).
Mitoxantrone binds to histones and DNA as analyzed on 
gel electrophoresis
In order to obtain information about the possible effect of
mitoxantrone on SE-chromatin components, the superna-
tants obtained from the interaction of mitoxantrone with
the chromatin were analyzed on agarose and SDS polyacr-
ylamide gel electrophoresis (Fig. 3). On the SDS gel (Fig
3A), in the absence of mitoxantrone, the proteins released
from the chromatin into solution are mostly core histones
and a trace of histone H1 (lane 2) as analyzed parallel to
the thymus histones (lane 1). This spontaneous release of
proteins has also been observed by Bartkowiak [24] and
represents the background of the experiment. In the pres-
ence of mitoxantrone and at low concentrations (<20 μg/
ml), the proteins pattern is very similar to the control but
at higher concentrations (>20 μg/ml), induce chromatin
compaction and tends the histones to be un-extractable
from the mitoxantrone treated samples leading to their
disappearance on the gel (Fig. 3A lanes 5–7).
Moreover, electrophoresis of DNA extracted from the
mitoxantrone treated samples and the control, shown in
Fig 3B, demonstrates that gradual increase in drug concen-
tration removes more DNA from the reaction mixture.
Cooperative binding of mitoxantrone to chromatin
The binding isotherm obtained from the equilibrium dial-
ysis experiment is shown in Fig. 4. The Scatchard plot of
the binding of mitoxantrone to SE-chromatin exhibits a
cooperative binding behavior, as illustrated by the posi-
tive slope observed in the low r regions of the binding iso-
Absorbance changes at 260 nm of the supernatants obtained  from the interaction of mitoxantrone with SE-chromatin  (diamond), SE-DNA (triangle) and calf thymus DNA (square) Figure 2
Absorbance changes at 260 nm of the supernatants 
obtained from the interaction of mitoxantrone with 
SE-chromatin (diamond), SE-DNA (triangle) and calf 
thymus DNA (square). Experimental condition was the 
same as described in figure 1.
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A: 15% SDS gel electrophoresis of the supernatants obtained  from the interaction of various concentrations of mitox- antrone with SE-chromatin Figure 3
A: 15% SDS gel electrophoresis of the supernatants 
obtained from the interaction of various concentra-
tions of mitoxantrone with SE-chromatin. Lanes 2–7 
are 0, 10, 20, 30, 40 and 60 μM of mitoxantrone respectively. 
Lane 1, calf thymus histones as a standard. B: Agarose gel of 
DNA extracted from the supernatants. Lane 1, EcoR1 DNA 
marker. Lanes 2–7 are the same as in gel A. Number of 
experiments was 3.
Scatchard plots of the binding of mitoxantrone to SE-chro- matin (diamond) and DNA (triangle) carried out in 10 mM  Tris-HCl pH 7.4 for 72 hours at 25°C Figure 4
Scatchard plots of the binding of mitoxantrone to 
SE-chromatin (diamond) and DNA (triangle) carried 
out in 10 mM Tris-HCl pH 7.4 for 72 hours at 25°C. 
Results are means of 3 individual experiments.Journal of Biomedical Science 2009, 16:31 http://www.jbiomedsci.com/content/16/1/31
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therm. The curve reaches a maximum at a value of r = 0.27
and decrease in the slope is observed at higher r values.
Drawing r versus Cf, as shown in the insert of Fig 4, clearly
demonstrates a sigmoid curve, that is, as Cf increases, r
rises rapidly and then levels off, indicating that the system
approaches to equilibrium or saturation. The binding of
mitoxantrone to chromatin represents a binding constant
of k = 7.1 × 106 M-1 and drawing ln r/n-r against ln Cf gives
a straight line with a slope of the nH (Hill coefficient)
which was 3, confirming the positive cooperative binding
of drug to chromatin.
The binding isotherm of DNA is also given in Fig. 4. It also
exhibits cooperative binding pattern with a binding con-
stant of k = 5.0 × 106 M-1 and nH value of 1.9. The result
clearly demonstrates lower binding affinity of mitox-
antrone to DNA compared to chromatin. The result is in
agreement with the cooperative binding of mitoxantrone
to DNA reported previously [25].
Mitoxantrone also interacts with the histones free in 
solution
Absorbance in the UV/Vis region has been successfully
used for the analysis of antracyclines-linker histones inter-
actions [26,27]. In this study, the purified histone pro-
teins were incubated in the presence and absence of
various concentrations of mitoxantrone and then absorb-
ance changes were monitored at 608 and 210 nm. Figure
5A shows the absorbance changes of the histones as a
function of drug concentration. As is seen, the absorbance
at 210 nm is considerably decreased upon addition of
mitoxantrone. This absorbance reduction is also observed
in the pattern of 480 nm which is exclusively related to the
wavelength of mitoxantrone. The results indicate that
drug molecules inter the sites of histones, which are active
in electron excitation.
The fluorescent emission spectra obtained from the inter-
action of mitoxantrone with the histones is also shown in
Fig 5B. Histones, in the absence of mitoxantrone exhibit
emission spectra in the position corresponding to tyrosine
emission with a maximum intensity at 305 nm (fluores-
cence emission spectra of tyrosine has also been provided
for comparison). Addition of mitoxantrone to the histone
solution reduces the fluorescence intensity of the histones
without any red shift in the emission maxima (Imax) as
drug concentration is increased. This clearly implies that
the binding of mitoxantrone to histones is dependent on
their accessibility to the environment.
To obtain further information about the binding of
mitoxantrone to histone proteins, we compared the sec-
ondary structure of the intact and histone- mitoxantrone
complex in the same experimental condition. As is shown
in Fig. 6, histones display a CD spectrum with negative
extremes at 209 and 220 nm (the former more intense);
whereas, mitoxantrone treatment caused a significant
decrease in the intensity of the peaks, especially at 209
A) Absorbance changes of histones upon mitoxantrone bind- ing Figure 5
A) Absorbance changes of histones upon mitox-
antrone binding. The reaction was carried out in 10 mM 
Tris-HCl pH 7.3 at 23°C. B) Fluorescence emission spectra 
of the histones in the presence and absence of various con-
centrations of mitoxantrone. All samples were prepared in 
10 mM Tris – HCl (pH 7.3) and incubation time after drug 
addition was 20 minutes. Excitation was at 278 nm. Spectra 
1–6 are 0, 10, 20, 30, 40, and 60 μM of mitoxantrone respec-
tively. Tyr: tyrosine spectrum given for comparison.
Far UV CD spectra of the histones in 10 mM Tris-HCl at pH  7.3 in the absence and presence of mitoxantrone Figure 6
Far UV CD spectra of the histones in 10 mM Tris-
HCl at pH 7.3 in the absence and presence of mitox-
antrone. Each spectrum was obtained at 25°C with a 10 mm 
path length cell. 1–4 are 0, 10, 20 and 40 μM of mitoxantrone 
respectively. All necessary corrections were made for back-
ground absorption.Journal of Biomedical Science 2009, 16:31 http://www.jbiomedsci.com/content/16/1/31
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nm, which implies that, the secondary structure of the
protein is perturbed upon drug binding.
Discussion
Mitoxantrone is an anthracycline analog with potent anti-
neoplastic activity and is distinctly different from doxoru-
bicin in its cytotoxicity to leukemia cells [28]. Numerous
studies on the binding of mitoxantrone to DNA have been
undertaken and all indicate that it exerts its biological
function by intercalation and also electrostatic cross-links
within DNA to stabilize the binding [7,8]. In the cell
nucleus, DNA is complexed with the histone proteins
making a defined structure known as nucleosome [16],
the structure that has been considered as a tool for the
study of genome function in cancer [29]. Therefore the
interaction of mitoxantrone with this nucleoprotein com-
plex and its individual components, will clarify the real
mechanism of drug action in the cell nucleus.
Although several attempts have been made to understand
the mechanism of mitoxantrone action [13,14,30], the
environment of nucleic acids in the cell nucleus, espe-
cially DNA-protein complex, may significantly modulate
the interaction. Despite the presence of numerous pub-
lished papers on the interaction of mitoxantrone with
DNA, to date, the effect of mitoxantrone on chromatin
has not been fully understood. In fact, this is the first
paper demonstrating the effect of mitoxantrone on chro-
matin and histones protein (in the absence of DNA) in
solution.
Our results suggest that mitoxantrone recognizes the chro-
matin structure with higher affinity than free DNA. Slight
increase in absorbance at 260 nm announces induction of
chromatin unfolding at very low concentration of mitox-
antrone (<10 μM), however, at higher concentrations the
interaction of mitoxantrone with chromatin is accompa-
nied by chromatin compaction/aggregation. The binding
of mitoxantrone to chromatin produces a very compact
structure that prevents the release or extraction of histone
proteins from such drug treated chromatin. Higher affin-
ity of mitoxantrone to chromatin is also confirmed by the
results obtained from the binding isotherms. Although
the binding is positive cooperative for both DNA and
chromatin, but K values are different. Moreover, mitox-
antrone strongly binds to histone proteins in solution,
and upon drug action, their secondary structure is
reduced. Fluorescence emission spectra exhibits quench-
ing of mitoxantrone with tyrosine chromophores of the
histones which are mainly located in their globular
domain. Severe binding of mitoxantrone to histones
implies that apart from DNA, histone proteins are also a
good candidate for mitoxantrone action at the chromatin
level; however, the mode of interaction is still unknown.
From the results it also seems that the behavior of mitox-
antrone -chromatin interaction differs considerably from
the interaction of anthracycline anticancer drugs such as
daunomycin and Adriamycin with chromatin. The
anthracyclines preferentially bind to less condensed struc-
ture of chromatin and the order is DNA>chromatin-
H1>chromatin [31,18], whereas in the case of mitox-
antrone, the affinity of drug to chromatin is higher than to
DNA.
In cancer cells, double stranded DNA is also associated
with histone proteins making nucleosomes, but because
of genetic or epigenetic changes of chromatin, the struc-
ture is more relaxed and loose compared to normal cells
[32]. This implies that, in cancer cells, mitoxantrone also
preferentially binds to nucleosome structure or partially
histone free DNA rather than DNA completely free of his-
tone (naked DNA). This is confirmed by our founding
that mitoxantrone shows strong affinity to histone pro-
teins. Although Oliveira Brett et al. (1998) have suggested
preferential interaction of mitoxantrone with single
stranded DNA using acidic condition [33]; we can not
speculate this phenomenon which needs extensive work
to be clarified.
Taking all together, it is finally concluded that mitox-
antrone binds to chromatin and produces a compact
structure, the statement which is in good agreement with
the anticancer activity of the drug which inhibits DNA and
RNA synthesis [10,11]. The results come in support of the
notion that the protein component of chromatin can also
be considered as a target for the activity of this antitumor
drug. Whether mitoxantrone interacts directly with the
histone proteins or cross linking occurs between the DNA
and histones is still unknown. Further insights into the
mechanism of mitoxantrone action at the chromatin level
especially the real binding sites on histone proteins
remain to be elucidated.
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